PSNLPersonalis, Inc.

PSNL Stock Price, Valuation & Chart | Personalis, Inc.

Compare

$16.730-0.33 (-1.93%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Medical - Diagnostics & Research PSNL intrinsic value PSNL calculated fair value vs price

Overview Financials Dividends Ratios

PSNL Historical price chart

PSNL Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization1.79B

PE Ratio-15.35

EPS-1.09

Trading Volume2.22M

Today's High/Low17.15/16.72

Dividend Yield0.00

52 Week High/Low18.89/4.73

Shares Outstanding106.75M

PSNL Financial Statement

PSNL Analyst ratings

PSNL Analysis & performance metrics

PSNL Company profile

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies…

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor…

PSNL Management team

Name

Position

Deepshikha Bhandari

Senior Vice President of Regulatory, Quality & Clinical Compliance

Christopher M. HallCEO

President, Chief Executive Officer & Director

Russ B. Altman M.D., Ph.D.

Co-Founder and Member of Clinical & Scientific Advisory Board

Aaron L. TachibanaCFO

Chief Financial Officer & Chief Operating Officer

Richard Chen M.D., M.S.

Executive Vice President of R&D and Chief Medical Officer

Euan Angus Ashley DPHIL, FRCP, M.D., Ph.D.

Co-Founder and Member of Clinical & Scientific Advisory Board

Stephen M. Moore J.D.

Senior Vice President, Chief Legal Officer & Corporate Secretary

Michael P. Snyder Ph.D.

Co-Founder and Member of Clinical & Scientific Advisory Board

Name

Position

Deepshikha Bhandari

Senior Vice President of Regulatory, Quality & Clinical Compliance

Christopher M. HallCEO

President, Chief Executive Officer & Director

Russ B. Altman M.D., Ph.D.

Co-Founder and Member of Clinical & Scientific Advisory Board

Aaron L. TachibanaCFO

Chief Financial Officer & Chief Operating Officer

Richard Chen M.D., M.S.

Executive Vice President of R&D and Chief Medical Officer

Euan Angus Ashley DPHIL, FRCP, M.D., Ph.D.

Co-Founder and Member of Clinical & Scientific Advisory Board

Stephen M. Moore J.D.

Senior Vice President, Chief Legal Officer & Corporate Secretary

Michael P. Snyder Ph.D.

Co-Founder and Member of Clinical & Scientific Advisory Board

Management Team

Deepshikha Bhandari

Senior Vice President of Regulatory, Quality & Clinical Compliance

Christopher M. HallCEO

President, Chief Executive Officer & Director

Russ B. Altman M.D., Ph.D.

Co-Founder and Member of Clinical & Scientific Advisory Board

Aaron L. TachibanaCFO

Chief Financial Officer & Chief Operating Officer

Richard Chen M.D., M.S.

Executive Vice President of R&D and Chief Medical Officer

Euan Angus Ashley DPHIL, FRCP, M.D., Ph.D.

Co-Founder and Member of Clinical & Scientific Advisory Board

Stephen M. Moore J.D.

Senior Vice President, Chief Legal Officer & Corporate Secretary

Michael P. Snyder Ph.D.

Co-Founder and Member of Clinical & Scientific Advisory Board

Management

Deepshikha Bhandari

Senior Vice President of Regulatory, Quality & Clinical Compliance

Christopher M. HallCEO

President, Chief Executive Officer & Director

Russ B. Altman M.D., Ph.D.

Co-Founder and Member of Clinical & Scientific Advisory Board

Aaron L. TachibanaCFO

Chief Financial Officer & Chief Operating Officer

Richard Chen M.D., M.S.

Executive Vice President of R&D and Chief Medical Officer

Euan Angus Ashley DPHIL, FRCP, M.D., Ph.D.

Co-Founder and Member of Clinical & Scientific Advisory Board

Stephen M. Moore J.D.

Senior Vice President, Chief Legal Officer & Corporate Secretary

Michael P. Snyder Ph.D.

Co-Founder and Member of Clinical & Scientific Advisory Board

Total 8 executives

PSNL Frequently asked questions

What is Personalis, Inc. (PSNL) Stock Price?

Current stock price of Personalis, Inc. (PSNL) stock is $16.730. The stock price is -1.93% lower in the session. The intraday range can be seen from this page. Volume of Personalis, Inc. (PSNL) stock is 2.22M.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Personalis, Inc. (PSNL) stock price going up or down today?

The stock price of Personalis, Inc. (PSNL) can change with earnings, company news, and overall market sentiment. Personalis, Inc. operates in the Healthcare / Medical - Diagnostics & Research market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Personalis, Inc. stock expensive at its current price?

Whether Personalis, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for PSNL on this page is -15.35. EPS on this page is -1.09. Compare those figures with peers and growth expectations before deciding if the current Personalis, Inc. price is justified.

How has the stock price of Personalis, Inc. (PSNL) performed historically?

Historical performance for Personalis, Inc. (PSNL) is shown on the price chart on this page. Review multi-period moves alongside volume to see how PSNL reacted to past earnings and market events.

Should I buy Personalis, Inc. (PSNL) stock, at this price?

Buying Personalis, Inc. (PSNL) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.